Ranbaxy Receives FDA Approval To Market A Generic Alternative To Macrobid(reg)
Nitrofurantoin Monohydrate/Macrocrystals Capsules are indicated only for the treatment of acute uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of Escherichia coli or Staphylococcus saprophyticus.
"We are delighted to receive approval from the U.S. FDA to market this product to add to our ever growing generic product portfolio. Our plans are to bring this product to the market as quickly as possible during the month of April," according to Jim Meehan, Vice President of Sales and Marketing for RPI, USA.
Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, USA, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.
Ranbaxy Laboratories Limited, India's largest pharmaceutical company, manufactures and markets brand and generic pharmaceuticals and Active Pharmaceutical Ingredients. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. Ranbaxy's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies" resulting in a number of products under development. The Company is selling its products in over 100 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 44 countries and manufacturing operations in 7 countries.
*Macrobid(reg) is a registered trademark of Proctor and Gamble Pharmaceuticals, Inc.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:
Lower, Angela. "Ranbaxy Receives FDA Approval To Market A Generic Alternative To Macrobid(reg)." Medical News Today. MediLexicon, Intl., 3 Apr. 2005. Web.
27 Jun. 2017. <http://www.medicalnewstoday.com/releases/22121.php>
Lower, A. (2005, April 3). "Ranbaxy Receives FDA Approval To Market A Generic Alternative To Macrobid(reg)." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.